Virios Therapeutics, Inc. completed a business combination with Sealbond Limited, acquiring Pharmagesic (Holdings) Inc. and issuing 211,383 shares of common stock and 2,108.3854 shares of Series A Preferred Stock, while also announcing a reverse stock split and a name change to Dogwood Therapeutics, Inc.